File Description: 

 

Effective Dec. 7, Duke will provide a very limited supply of Emergency Use Authorized (EUA) monoclonal antibody infusions to outpatients with mild to moderate COVID-19 infection. Because of the limited supply of doses, only patients at very high risk for severe COVID-19 infection or hospitalization should be considered for this treatment. This document includes the eligibility criteria and process for providing these products to a small number of patients. Uploaded 1.19.21

The information on this site is intended solely for the internal use by Duke University Health System, its medical staff, clinicians and staff and any and all content or services available on or through this website is prohibited to be shared with external parties with the exception of those marked as patient communications that would be disclosed to patients.